










 


 










MPM Capital - Powering Breakthroughs in Life Sciences




























































MPM Focus Area
Personalized therapeutics forgenetically defined cancerWatch Now Chris Bardon, MD Oncology Impact FundDiscusses Advances in Cancer Therapies Bloomberg Capital Markets, June 2016
Related Investment: Epizyme





Companies









MPM Investment Strategy 
				MPM Capital works with leading scientists to create companies that seek to address unmet needs and change the face of medicine across all therapeutic areas. MPM is currently investing out of BV2014, its most recent venture fund. In 2015 MPM partnered with UBS to create the UBS Oncology Impact Fund (OIF), an innovative impact investing fund focused exclusively on oncology that will invest in both private and public equities. OIF will support both basic cancer research as well as access to cancer care in developing countries. 			




Fund

All
BV2014
Oncology Impact Fund



Investments

Current
Exited



Exit Type

All
IPO
M&A



Focus Area

All
Oncology
Other










23andMe
Genetic reports for consumers to better appreciate their ancestry

Other
Current









28-7
Small-molecule therapeutics that modulate miRNAs for treatment

Oncology
Current









Affymax, Inc.
Previously committed to developing novel drugs

Other
Exited









Aires
Clinical stage pharmaceutical company for pulmonary disorders

Other
Exited









Alinea Pharmaceuticals, Inc.
Previously developed new treatments for metabolic conditions

Other
Exited









Allozyne, Inc.
Cancer and inflammatory disease therapeutic company

Oncology
Exited









Alnara
Orally-delivered protein therapeutics to treat metabolic diseases

Other
Exited









Amphivena
Developing bispecific TandAbs as a novel immunotherapy for hematological disorders

Oncology
Current









Anthera
Developing drugs for autoimmune diseases

Other
Exited









Aratana
Provides innovative therapies for companion animals

Other
Current









Archus Orthopedics, Inc.
Previously developed implants to treat spine disorders 

Other
Exited









ARYx Therapeutics, Inc.
Previously focused on molecular design

Other
Exited









Astute Medical
Improving the diagnosis of high-risk medical conditions

Other
Current









Atopix Therapeutics, Inc.
Developing novel treatments for asthma

Other
Exited









Barrier Therapeutics, Inc.
Specialized in dermatological creams and gels

Other
Exited









BioMarin
Innovative therapeutics to patients with serious unmet medical needs

Other
Exited









Blade Therapeutics
A discovery stage company focused on developing fibrosis treatments

Other
Current









Celladon
Developing a transformative therapy for heart failure

Other
Exited









Cellerant Therapeutics, Inc.
novel immunotherapies for oncology and blood-related disorders

Oncology
Exited









Cerecor Inc.
Developing innovative treatments for patients with CNS disorders

Other
Exited









Ceregene, Inc.
Development and manufacturing of gene therapies 

Other
Exited









Cerimon Pharmaceuticals, Inc.
Developed and commercialized therapeutics for autoimmune diseases

Other
Exited









CHF Solutions, Inc.
Manufactures medical devices for cardiac care. 

Other
Exited









Chiasma
Developing oral drugs that were previously only available by injection

Other
Current









Clinical ink
Modernize clinical trials with eSource & patient engagement tools

Other
Current









Conatus
Developing novel therapeutics for liver diseases

Other
Exited









CoStim
Developing novel antibodies for cancer immunotherapy

Oncology
Exited









CoTherix, Inc.
Licensing of therapeutic products for cardiopulmonary diseases

Other
Exited









DigiTx Partners
Digital health investment partnership with Astellas Pharma

Other
Current









Dragonfly Sciences, Inc.
developing a new class of biosimilar products

Other
Exited









EKR Therapeutics
Provides acute-care specialty products

Other
Exited









Elixir Pharmaceuticals, Inc.
Develops novel pharmaceuticals for the treatment of metabolic diseases

Other
Exited









EndoGastric Solutions, Inc.
Endoluminal treatment of gastroesophageal reflux disease

Other
Exited









Endologix
Provides optimal solutions for endovascular aortic repair

Other
Current









EnteroMedics, Inc.
developer of vBloc® neurometabolic therapy

Other
Current









Epizyme
Personalized therapeutics for patients with genetically defined cancer

Oncology
Current









ForteBio
Develops analytical systems that enable real-time analysis of biomolecular interactions 

Other
Exited









Harpoon Therapeutics
T cell redirection to deliver deep remissions

Oncology
Current









Helicos Biosciences Corporation
Genetic analysis for the research, drug discovery and diagnostics 

Other
Exited









Hypnion, Inc.
development of novel therapeutics for (CNS) disorders

Other
Exited









Iconic
Developing therapeutics for serious eye disorders

Other
Current









Idenix
Discovers and develops drugs for human viral diseases

Other
Exited









IDUN Pharmaceuticals, Inc.


Other
Exited









Innovative Spinal Technologies, Inc.
Developed treatments for spinal disorders 

Other
Exited









Intercell AG
Modern prophylactic and therapeutic vaccines 

Other
Exited









Intracel Holdings Corporation
Development and commercialization of cancer vaccines

Other
Exited









IOmx Therapeutics AG
Targeting T cell evasion to treat cancer

Oncology
Current









iPierian
Developing anti-Tau protein antibodies for neurodegenerative disease

Other
Exited









KaloBios Pharmaceuticals, Inc.
developing monoclonal antibodies for cancer care

Oncology
Exited









MacroGenics, Inc.


Oncology
Exited









Maverick Therapeutics, Inc.
Inducible T cell-redirecting antibodies

Oncology
Current









Memory Pharmaceuticals Corp.
Developed drug candidates for the treatment of CNS disorders

Other
Exited









Meritage Pharma
Treatment for eosinophilic esophagitis (EoE)

Other
Exited









Mitobridge
Discovers and develops novel drugs that enhance mitochondrial function

Other
Current









Motus Therapeutics, Inc.
Developing therapies for severe gastric mobility disorders

Other
Exited









Neosil
Manufactures dermatology-focused specialty pharmaceutical products

Other
Exited









NeoVista, Inc.
Technologies for age related mucular degeneration

Other
Exited









NeuroMed Pharmaceuticals, Inc.
Produces pain therapies in the US

Other
Exited









Nevro
Developing a high-frequency stimulation technology for chronic pain

Other
Exited









Oncorus
Developing a next-generation immunotherapy platform to treat cancer

Oncology
Current









Oxagen Limited
A privately-held biopharmaceutical company

Other
Current









Pacira
Acute care products including EXPAREL for post-surgical analgesia

Other
Exited









Peptimmune, Inc.
Designs peptides for therapeutics, diagnostic kits & antibodies

Other
Exited









Pernix Therapeutics, Inc.
Specialty, primary care and generic medicines

Other
Exited









Pharmasset
Discovering and developing novel drugs to treat viral infections

Other
Exited









PharmAthene, Inc.
Acquire and develop products identified as urgent priorities

Other
Exited









Poniard Pharmaceuticals, Inc.
Discovery, development and commercialization of oncology products

Other
Exited









Portola Pharmaceuticals, Inc.
A biopharmaceutical company in the hematologic diseases fields 

Other
Exited









Potenza Therapeutics
Developing novel immunotherapies for the treatment of cancer

Oncology
Current









Proteon Therapeutics
Developing a therapy to improve dialysis vascular access

Other
Current









QuatRx Pharmaceuticals Company
Treatment of moderate to severe dyspareunia FDA approved in Feb 2013

Other
Exited









Radius Health
Novel, differentiated therapeutics for patients with osteoporosis

Other
Current









Raze Therapeutics
Developing novel anti-tumor agents through mitochondrial one-carbon me

Oncology
Current









Repare Therapeutics
Targeting genetically-defined cancer weaknesses

Oncology
Current









Rhythm
Developing peptide therapeutics for metabolic diseases

Other
Current









Rigel Pharmaceuticals, Inc.
Small-molecule development for inflammatory and autoimmune diseases

Oncology
Exited









Rinat Neuroscience Corp.
Develops treatment of diseases and disorders of the nervous system

Other
Exited









SAI
Drug discovery, development, and manufacturing services

Other
Exited









Selexys
Developing novel products to treat inflammatory diseases

Other
Exited









Semma Therapeutics
Developing cell-based transformative therapies for diabetes patients

Other
Current









Sideris Pharmaceuticals, Inc.
Development of new treatments for transfusion related iron overload

Other
Exited









Solasia
Developing, commercializing oncology & oncology supportive care drugs

Oncology
Exited









Somaxon Pharmaceuticals, Inc.
Developed Silenor for treatment of insomnia 

Other
Exited









Surface Logix, Inc.
Enhancing molecular functionality of pharmaceuticals

Other
Exited









Syndax
Developing and commercializing epigenetic therapies for cancer

Oncology
Current









TCR2, Inc.
Focused on engineering T cells for cancer therapy

Oncology
Current









Tercica, Inc.
Developed Increlex for treatment of primary IGF-1 deficiency

Other
Exited









Tetherex Pharmaceuticals Corporation
Operates in the healthcare industry focusing on biotechnology business

Other
Current









Theraclone Sciences, Inc.
Screening technology for antibodies that ward off disease 

Other
Exited









Tizona Therapeutics, Inc.
Regulatory T cell suppression as a novel approach to fighting cancer

Oncology
Current









Trieza Therapeutics
Immunomodulatory oncolytic virus therapeutics

Oncology
Current









TriNetX
Platform to improve clinical research, study design & recruitment

Other
Current









True North Therapeutics
Developing drugs which selectively inhibit the complement system

Other
Exited









Vaccinogen, Inc.
Personalized vaccines to fight disease 

Oncology
Other
Current









Valeritas
Marketing a disposable insulin delivery device

Other
Current









Vascular
Developing a novel antibody for diabetic nephropathy

Other
Current









Verastem, Inc.
Treating cancer by the targeted killing of cancer stem cells

Oncology
Exited









Verus Pharmaceuticals, Inc.
 Pediatric-oriented specialty pharmaceutical company

Other
Exited









Xanodyne Pharmaceuticals, Inc.
Integrated specialty pharmaceutical company 

Other
Exited
















MPM Team
				MPM's Team is comprised of innovators, entrepreneurs, executives & investors			



Role

Investment Team
Medical & Scientific Advisors
Operations Team



Location

All
Cambridge
San Francisco










									Patrick Baeuerle								


Patrick Baeuerle, Ph.D.
Managing Director

																					Cambridge 																			
Read Bio







									Chris  Bardon								


Christiana Bardon, M.D.
Managing Director

																					Cambridge																			
Read Bio







									Vinay Bhaskar								


Vinay Bhaskar, Ph.D.
Principal

																					San Francisco 																			
Read Bio







									Laura Brass 								


Laura Brass, Ph.D., M.B.A.
Managing Director

																					Cambridge 																			
Read Bio







									Lauren Cauley								


Lauren Cauley
Chief Financial Officer

																					Cambridge 																			
Read Bio







									Thomas Ebeling								


Thomas Ebeling
Medical and Scientific Advisor (OIF)


Read Bio







									Stephen Elledge								


Stephen J. Elledge,  Ph.D.
MEDICAL AND SCIENTIFIC  ADVISORY BOARD (MPM & OIF)


Read Bio







									Luke Evnin								


Luke Evnin, Ph.D.
Managing Director

																					San Francisco 																			
Read Bio







									Mitchell  Finer Ph.D.								


Mitchell Finer Ph.D.
Managing Director

																					Cambridge 																			
Read Bio







									Todd Foley								


Todd Foley, M.B.A.
Managing Director

																					Cambridge 																			
Read Bio







									Shinichiro Fuse								


Shinichiro Fuse, Ph.D.
Principal

																					Cambridge 																			
Read Bio







									Ansbert Gadicke								


Ansbert Gadicke, M.D.
Managing Director

																					Cambridge 																			
Read Bio







									Bard Geesaman								


Bard Geesaman, M.D., Ph.D.
Managing Director

																					Cambridge 																			
Read Bio







									William Greene								


William Greene, M.D.
Venture Partner

																					San Francisco 																			
Read Bio







									William Hahn								


William C. Hahn, M.D., Ph.D.
Medical and Scientific Advisor (OIF)


Read Bio







									Dan Hicklin								


Dan Hicklin, Ph.D.
Managing Director

																					Cambridge 																			
Read Bio







									Robert Horvitz								


H. Robert Horvitz, Ph.D.
Medical and Scientific Advisory Board (MPM & OIF)


Read Bio







									Ed Hurwitz								


Ed Hurwitz, J.D., M.B.A.
Managing Director

																					San Francisco 																			
Read Bio







									Briggs Morrison								


Briggs Morrison, M.D.
Managing Director

																					Cambridge 																			
Read Bio







									Vas Narasimhan								


Vas Narasimhan, M.D.
Medical and Scientific Advisory Board (MPM)


Read Bio







									Gary Patou								


Gary Patou, M.D.
Managing Director

																					San Francisco 																			
Read Bio







									Sarah Reed								


Sarah Reed
Chief Operating Officer and General Counsel

																					Cambridge 																			
Read Bio







									Tony Rosenberg								


Tony Rosenberg
Managing Director

																					Cambridge 																			
Read Bio







									David Ryan								


David P. Ryan, M.D.
Medical & Scientific Advisor (OIF)


Read Bio







									Kazumi Shiosaki								


Kazumi Shiosaki, Ph.D.
Managing Director

																					Cambridge 																			
Read Bio







									Greg Sieczkiewicz								


Greg Sieczkiewicz, J.D., Ph.D.
Managing Director & Chief IP Counsel

																					Cambridge 																			
Read Bio







									Elizabeth Stoner								


Elizabeth Stoner, M.D.
Managing Director

																					Cambridge 																			
Read Bio







									Chris Varma								


Chris Varma, Ph.D.
Entrepreneur-in-Residence

																					Cambridge 																			
Read Bio














Contact Us

info@mpmcapital.com



Cambridge, MA


								450 Kendall Street								
								Cambridge, MA  02142								


Phone | 617-425-9200

 


see full map / get directions

 

San Francisco, CA


								601 Gateway Boulevard								
								Suite 350								
																    South San Francisco, 
																CA 
								94080								

Phone | 650-553-3300

 


see full map / get directions

 
 



 

Print

Terms Of Use & Disclosures














2017

July 27, 2017
MPM’s Chris Bardon Talks to BioWorld About Recent Pharma R&D Restructuring
Trends point to pharma focus on signing more early stage partnerships


July 17, 2017
Radius Health Appoints Jesper Høiland as President and Chief Executive Officer
Leading the Next Stage Of Growth and Value Creation As A Fully Integrated Commercial Biotech Company


June 28, 2017
Semma Therapeutics Mentioned in WSJ article “Biotech Startups’ Cell-Based Diabetes Attack”



June 22, 2017
MPM and Versant Venture Co-Lead Series A Financing of Repare Therapeutics



June 21, 2017
Proteon Therapeutics Announces $22.0 Million Private Placement



June 20, 2017
Visionary Scientist Stephen J. Elledge Joins MPM Capital’s Medical and Scientific Advisory Board



June 13, 2017
Accomplished Oncologist and Scientist William C. Hahn Joins MPM Capital’s Oncology Impact Fund Advisory Board



June 8, 2017
TCR2 Therapeutics to Debut Positive Solid Tumor Data on its Novel TRuC™ Engineered T Cell Platform at the World Preclinical Congress



June 6, 2017
Radius Presents Positive Data From A Fully Enrolled Ongoing Phase I Study for Investigational Drug Elacestrant (RAD1901) at the 2017 American Society of Clinical Oncology Annual Meeting (ASCO)



May 25, 2017
Amgen vet Patrick Baeuerle inspires a $45M round from A-list VCs for a next-gen I/O drug platform



May 25, 2017
Harpoon Therapeutics Announces Completion of $45M Series B Financing



May 23, 2017
MPM Portfolio Company True North Therapeutics Acquired by Bioverativ, Inc
Upfront payment of $400M plus assumed cash, with additional payments of up to $425M contingent on the achievement of future milestones


May 18, 2017
Syndax Shares Soar as Lead Drug Clears a Mid-Stage Cancer Drug Study Hurdle



May 4, 2017
Conatus Announces Exercise of License Option for Global Development and Commercialization of Emricasan Following Notice of Initiation of Phase 2b ENCORE-LF Clinical Trial in NASH Cirrhosis



May 3, 2017
Inside Perspectives on Cancer Immunotherapy: An Interview with MPM’s Christiana Bardon



April 28, 2017
FDA Approves MPM Portfolio Company Radius Health’s TYMLOS™ (abaloparatide)
Bone Building Agent for the Treatment of Postmenopausal Women with Osteoporosis at High Risk for Fracture


April 17, 2017
Meet One the Most Successful German Biotech Leaders Ever Read more about MPM’s Patrick Baeuerle



April 5, 2017
MPM Managing Director Chris Bardon Named a Top-40 Transformer
Top innovation gurus leading the biopharma industry's transformation are recognized by MM&M  


April 4, 2017
MPM Portfolio Company Oncorus Nominated for 2017 NEVY Award as Hottest Early-Stage Startup Therapeutics



April 4, 2017
Syndax Pharmaceuticals Adds Biopharmaceutical Industry Leader Keith A. Katkin to Board of Directors



February 16, 2017
Rhythm Announces Completion of $41 Million Mezzanine Financing
— Proceeds to finance significant expansion of genetic obesity clinical trials —


February 7, 2017
Chris Varma, Co-founder and Former President and CEO of Blueprint Medicines, Joins MPM as Entrepreneur-in-Residence



January 11, 2017
MPM Portfolio Company Maverick Therapeutics and Takeda Announce Five-year Collaboration to Advance T-Cell Engagement Therapies



January 5, 2017
Accomplished Biotech Investor Ed Hurwitz Joins MPM as Managing Director


2016 
December 19, 2016
MPM Portfolio Company, Astute Medical, Forms Strategic Partnership with Bio-Techne



December 19, 2016
Novartis Signs Exclusive Option, Collaboration and License Agreement with MPM Portfolio Company Conatus Pharmaceuticals Inc.



December 15, 2016
Oncorus®, Inc. Announces Additional Series A Financing Support From Astellas Venture Management LLC



December 13, 2016
Harpoon Therapeutics Appoints Gerald McMahon, Ph.D., as President and CEO



December 8, 2016
TCR2 Therapeutics Launches from Stealth Mode to Accelerate Development of Novel Cancer Immunotherapies
- $44.5M Series A Financing Led by MPM Capital and F2 Ventures -


December 2, 2016
Chris Bardon, MPM Managing Director, Comments to Bloomberg on New Approaches to Medical Philanthropy
Read full article – “A Few Billionaires Are Turning Medical Philanthropy on Its Head” 


November 28, 2016
Epizyme Announces Fast Track Designation for Tazemetostat in DLBCL and Provides Tumor Program Update



November 21, 2016
Novartis Acquires MPM Portfolio Company Selexys Pharmaceuticals Corporation and SelG1 Antibody for Reduction of Pain Crises in Sickle Cell Disease



November 8, 2016
Harpoon Therapeutics Appoints Hans-Peter Gerber, PhD, As Chief Scientific Officer



November 7, 2016
Semma Therapeutics Announces Mark Fishman, M.D. Has Joined Its Board of Directors as Chairman



October 31, 2016
MPM Portfolio Company Epizyme Expands Clinical Programs through Cooperative Research and Development Agreements with the National Cancer Institute



October 27, 2016
Motus Therapeutics Inc., a Subsidiary of MPM Portfolio Company Rhythm Holding Co., LLC is to be Acquired by Allergan
Acquisition Announced Following Positive Results for Phase 2b Clinical Trial of Treatment for GI Disorders


October 13, 2016
True North Therapeutics Receives FDA Orphan Drug Designation for TNT009 for the Treatment of Autoimmune Hemolytic Anemia, Including Cold Agglutinin Disease (CAD)



October 11, 2016
Pacira Pharmaceuticals’ Kristen Williams is Honored as 1 of 15 “Fierce Women in Biopharma 2016”
Learn why Kristen stands out among women in the industry


September 22, 2016
iOmx Therapeutics Raises EUR 40 Million in Series A round
Company establishes top-tier investor base consisting of MPM Capital, Sofinnova Partners, Wellington Partners and Merck Ventures


September 19, 2016
Three MPM Portfolio Companies (Blade, Oncorus & Rhythm) Named to FierceBiotech’s “2016 Fierce 15” List



September 19, 2016
Radius Announces Publication of Additional Positive Results from the Phase 3 Active Trial of Osteoporosis Treatment



September 14, 2016
Tizona Therapeutics, Inc. Appoints George Golumbeski, Ph.D., to its Board of Directors



August 16, 2016
Osteoporosis, a Disease With Few Treatment Options, May Soon Have One More
 Read coverage in NY Times and in Press Release


August 15, 2016
Aratana Secures Third FDA Approval
Animal pain drug expected to be available to veterinarians in the fall of 2016


August 11, 2016
Harvard Medical School Appoints MPM Medical and Scientific Advisory Co-Chair George Daley as New Dean
Read more in The Boston Globe


August 10, 2016
Iconic Therapeutics Announces Final Close of Series C Financing With Additional $10 Million Investment



August 1, 2016
Astellas and MPM Capital Launch DigiTx Partners



July 26, 2016
MPM Portfolio Company Blade Therapeutics Featured in the San Francisco Business Times
The July 19 article, “Taking it personally, cutting–edge biotech snags $45 million,” discusses the latest round of funding for Blade, a company focused on finding therapies for fibrotic disease, and MPM Co-Founder Luke Evnin’s personal commitment to the cause.


July 21, 2016
Rhythm Announces New England Journal of Medicine Publication of Setmelanotide Phase 2 Data for Treatment of POMC Deficiency Obesity
Significant weight loss with targeted treatment for patients with rare genetic defect in critical weight regulation pathway


July 20, 2016
Former Bluebird Bio (BLUE) CSO Takes the Reins at Oncorus; Startup Launches with $57 Million Series A



June 16, 2016
MPM Portfolio Company Semma Therapeutics Featured in Boston Globe
Boston-area hospitals have teamed up with the Harvard Stem Cell Institute and Semma Therapeutics to make personalized cell-based therapies and organize clinical trials.


June 2, 2016
Chris Bardon, Managing Director for the Oncology Impact Fund, on Bloomberg Capital Markets
Discussing Advances in Cancer Therapies as the 2016 ASCO Annual Meeting Gets Underway


May 27, 2016
TriNetX Enters into Collaboration with Celgene
Advance Clinical Trial Design and Research for Next-Generation Medicines Planned


May 18, 2016
Aratana Therapeutics Granted FDA Approval of ENTYCE®
First-of-its-Kind Ghrelin Mimetic


May 3, 2016
MPM Launches $471 Million Social Impact Oncology Fund



April 29, 2016
UBS Cancer Fund Shows Power of Impact Investing
A new oncology fund will finance academic research and access to cancer care in developing countries


April 28, 2016
UBS, MPM Seek Big ‘Impact’ in Cancer Drugs with $471M Fund
By Marie Powers, BioWorld Today, April 28, 2016


April 27, 2016
UBS Raises Record $471 Million for Oncology Impact Fund
BioSpace.com 4/27/2016


March 21, 2016
Aratana Therapeutics Granted First FDA Approval
Galliprant for the Control of Pain and Inflammation Associated with Osteoarthritis in Dogs


March 14, 2016
Chiasma Initiates Phase 3 Trial to Support European Registration of Octreotide Capsules for Patients with Acromegaly



March 8, 2016
Tizona Therapeutics, Inc., Completes $43 Million Series B Financing



March 6, 2016
Radius Health Submits New Drug Application to the U.S. Food and Drug Administration for Abaloparatide-SC for the Treatment of Postmenopausal Women with Osteoporosis



March 3, 2016
Nasdaq Welcomes Syndax Parmaceuticals, Inc. to The Nasdaq Stock Market



January 9, 2016
Iconic Therapeutics Closes Series C Financing


2015 
October 15, 2015
Semma Therapeutics named FierceMedicalDevices’ 2015 Fierce 15



August 27, 2015
Syndax Enters Clinical Trial Collaboration in Cancer Immunotherapy Combining Entinostat and Atezolizumab



August 24, 2015
Syndax Raises $80 Million in Series C Financing



August 17, 2015
Rhythm Subsidiary Raises $40 Million in Oversubscribed Financing
Financing to advance Rhythm Metabolic, Inc.'s setmelanotide program for rare genetic disorders of obesity


August 15, 2015
Epizyme Appoints Robert Bazemore President and Chief Executive Officer



July 16, 2015
Chiasma, Inc. Prices Initial Public Offering of Common Stock



July 10, 2015
Taking Clinical Trials Out of the Dark Ages (Clinical Ink)



June 23, 2015
Briggs W. Morrison, M.D., CEO of Syndax, Appointed Key Strategic Advisor  to MPM Capital



June 15, 2015
Chiasma Submits New Drug Application to U.S. FDA  for Octreotide Capsules in Acromegaly
Submission based on positive results from Phase 3 clinical trial


June 1, 2015
K. Peter Hirth, PhD, Joins Iconic Therapeutics as Board Member and Senior Scientific Advisor



May 21, 2015
MPM Capital appoints Pablo J. Cagnoni, M.D., former Onyx Pharmaceuticals President, as Managing Director and CEO of MPM immunotherapy portfolio company Vesuvius



May 14, 2015
MPM closes $400 million fund



May 5, 2015
23andMe Launches the Lupus Research Study in Collaboration with Pfizer Inc.
With Lupus Awareness Month Underway, Study Aims to Build a 5,000-Patient Lupus Cohort to Advance Understanding of the Disease


April 22, 2015
Astellas Pharma and Potenza Therapeutics Partner to Build a Portfolio of Immuno-oncology Therapeutics
Exclusive Collaboration Includes Option for Astellas to Acquire Potenza


April 15, 2015
Novartis International Global Head M&A and Licensing Anthony Rosenberg to join as Managing Director, effective April 1, 2015
- To serve as strategic advisor and on MPM portfolio boards to build leading companies -


March 24, 2015
Biotech Startup to Fight Diabetes on the Cellular Front
Semma Therapeutics seeks to turn success in stem research lab into a way to encourage insulin production


March 24, 2015
Semma Therapeutics Announces $44 Million in Funding Led by MPM Capital to Develop Cell Therapy for Treating Type 1 Diabetes; Signs Agreement with Global Pharmaceutical Company



March 16, 2015
Ebb & Flow: Chiasma’s Private Decision



March 16, 2015
Chiasma Announces Mark Leuchtenberger as Chief Executive Officer
Proven Business Leader to Oversee Commercialization of Octreotide Capsules


March 12, 2015
23andMe to Create Therapeutics Group, Appoints Scientific Luminary, R&D Executive Richard Scheller, Ph.D. to Lead
Dr. Scheller Joins 23andMe’s Executive Leadership Team as Chief Science Officer and Head of Therapeutics


March 11, 2015
MPM Capital Announces Immuno-Oncology Pioneer Patrick Baeuerle to serve as Managing Director
-Top scientist and drug developer joins MPM senior team advancing breakthroughs and discoveries 


March 10, 2015
Radius (RDUS) Announced Today That It Has Acquired The License To Develop And Market RAD1901 In Japan
Dinesh Purandare Hired (Former Sanofi (SAN.PA) Oncology Executive To The Position Of Senior Vice President (SVP) And Head Of Global Oncology At Radius )


February 27, 2015
Chiasma Announces Completion of $70 Million Series E Financing



February 27, 2015
Verastem Receives Orphan Drug Designation From FDA For VS-5584 In Mesothelioma



February 24, 2015
Chiasma Appoints David Stack as Chairman of the Board; John A. Scarlett, M.D. Joins Board of Directors



February 20, 2015
Syndax Says Immuno-oncology Discovery Happened Instead of an IPO



February 10, 2015
Chiasma Inc. Releases Newly Published Phase 3 Study Results
Show Positive Outcomes For Octreotide Capsules In People With Acromegaly, A Serious Hormonal Disorder


February 9, 2015
Radius, Celladon and Nevro Among Top IPOs in 2014
MPM has #1, 8 and 10 out of the top 14


January 1, 2015
Radius:  The Top Performing IPO of 2014
Radius, which is developing treatments for osteoporosis, is up 364% since pricing its June 6 initial public offering at 8

2014 
December 22, 2014
Radius Announces Positive Phase 3 Top-Line Results



December 15, 2014
For Venture Capital, Biotech is Where It’s Really At



August 4, 2014
Aratana Featured:  Start-Ups Work on Biotech Drugs for Pets



June 17, 2014
True North snags $22M and sets course for the clinic with a rare disease drug



April 29, 2014
iPierian acquired by Bristol-Myers Squibb
Advances discovery strategy to pursue therapeutics for genetically defined diseases


April 16, 2014
Iconic Therapeutics Raises $20 Million to Advance Clinical Development of Wet AMD Program
William Greene, MD, Appointed Chief Executive Officer


April 14, 2014
Celladon Receives Breakthrough Therapy Designation from FDA
MYDICAR is First Gene Therapy Reported to Receive Breakthrough Designation from FDA’s Center for Biologics Evaluation and Research (CBER)


February 18, 2014
CoStim Pharmaceuticals, Inc. Acquired by Novartis



January 27, 2014
MPM Capital and Kleiner Perkins Caufield & Byers top the list of investors with the most 2013 IPOs



January 7, 2014
Epizyme and Celgene Advance EPZ-5676 DOT1L Inhibitor Clinical Program to Benefit Cancer Patients with Acute Leukemias, Achieving $25 Million Clinical Proof of Concept Milestone





2017
2016
2015
2014











X










X










X



































SUMMIT INVESTORS GE IX/VC IV, LLC - Pooled Investment Fund- Allgaier  FormDs.com - SEC filings of fundraisings and investments in hedge funds, private equity firms, startups, and growing companies 











 FormDs.com 





 Newest
 Filter
 Local




 









SUMMIT INVESTORS GE IX/VC IV, LLC

      Industry: Pooled Investment Fund
      (See others in industry)

Address:



    222 Berkeley Street, 18 Th Floor  
    Boston, MA, 02116Phone: 617-824-1100 




Filings



Date
FilingType
Reported Sold
Incremental Cash 
Type
Exemptions
Link to Raw Filing




	2017-04-26


New


Yet to Sell


$0


Equity Only


06b 3C 3C.1


SEC link




	2016-10-18


New


Yet to Sell


$0


Equity Only


06b 3C 3C.1


SEC link




	2016-03-31


New


Yet to Sell


$0


Equity Only


06b 3C 3C.1


SEC link




	2015-09-28


New


Yet to Sell


$0


Equity Only


06b 3C 3C.1


SEC link






Directors and Executives (Current and Past)



Name
Role



 Matthias G. Allgaier 
 Executive 


 Darren M. Black 
 Executive 


 John R. Carroll 
 Executive 


 Peter Y. Chung 
 Executive 


 Scott C. Collins 
 Executive 


 Christopher J. Dean 
 Executive 


 Mark A. Delaar 
 Executive 


 Robin W. Devereux 
 Executive 


 Bruce R. Evans 
 Executive 


 Leonard C. Ferrington 
 Executive 


 Charles J. Fitzgerald 
 Executive 


 Craig D. Frances 
 Executive 


 James M. Freeland 
 Executive 


 Greg S. Goldfarb 
 Executive 


 Todd D. Hearle 
 Executive 


 Thomas H. Jennings 
 Executive 


 Walter G. Kortschak 
 Executive 


 Martin J. Mannion 
 Executive 


 Gregg J. Nardone 
 Executive 


 Thomas S. Roberts 
 Executive 


 Peter L. Rottier 
 Executive 


 Han Sikkens 
 Executive 


 Christian R. Strain 
 Executive 


 Alexander D. Whittemore 
 Executive 


 Alexander D. Whittmore 
 Executive 










 

PETER ROTTIER's involvement in venture capital (via Summit Investors Ge Ix/vc Iv Llc, Perforce Holdings Inc)































Want to see more?Want to find out who got funded, and who’s funding the next big thing? in real time? all across the world? tailored to your specific areas of focus?100+ deals per dayGet access to the most exhaustive worldwide funding watch on the web!Comprehensive funding informationKnow about who invested in a company, which sites covered the event, the funding history, etc.Exclusive insightsView original analytics such as most dynamic industries, most active investors, and more!Stay aware!Get emailed when deals critical to your business happen. Filter by region, industry and topics of interest.As seen onHave a login?Sign inRegister now!It's free!Use your social accountOr fill in the quick form:Register nowpromise we won't spamSign invia your social account:via your existing WGF account:Remember meRegister, it's freeForgot your password?SIGN INForgot your password?Enter your e-mail and we will send you your new password.reset passwordThe world's largest funding base/people/230042-peter-rottiersection=people&subsection=detail&id=230042




			Search deals by company name, industry, location, investors...			
			




SEARCH


PETERROTTIERGet alertedif PETER ROTTIER gets funded!PETER ROTTIERSummit Investors Ge Ix/vc Iv Llc - Executive OfficerPerforce Holdings Inc - DirectorDeals involving PETER ROTTIERUndisclosed raised with Summit Investors Ge Ix/vc Iv Llc on September, 2015$97,417,056 raised with Perforce Holdings Inc on February, 2016Please note that all data is automatically extracted and errors can occur.The WhoGotFunded team has not necessarily reviewed the information in this page and has not determined if it is accurate and complete.Some of the profile information was collected using the Crunchbase API. For more details on the profile, please check PETER ROTTIER on Crunchbase.Inaccurate Data? Help us improve WhoGotFunded: post a comment!










 


 




Summit Partners | Contact Information





















Summit Partners










Connect

Boston
Menlo Park
London



Connect with us: Please contact us at one of our offices below, or contact a member of our Investment Team

@SummitPartners
LinkedIn Profile
Join Our Newsletter
Media Inquiries: Meg Devine






Boston

Summit Partners

222 Berkeley Street, 18th floor
Boston, MA 02116
United States

T: +1 617.824.1000
F: +1 617.824.1100

Office Information







Menlo Park

Summit Partners

200 Middlefield Road, Suite 200
Menlo Park, CA 94025
United States

T: +1 650.321.1166
F: +1 650.321.1188

Office Information







London

Summit Partners LLP

Queensberry House, 3rd Floor3 Old Burlington Street
London W1S 3AE
United Kingdom

T: +44 (0)20 7659 7500
F: +44 (0)20 7659 7550

Office Information














Home | Golub Capital

























































  









SPEED AND CREATIVITY, FUELED BY DATA AND INSIGHTS.
OPPORTUNITY AWAITS.Middle Market LendingProvides senior, one-stop and second lien loans to U.S. middle market companiesLate Stage LendingProvides flexible debt that allows fast-growing technology companies to expand without further equity dilutionBroadly Syndicated LoansInvests in liquid senior secured loans to larger companiesGet to know Golub Capital.Golub Capital is a nationally recognized credit asset manager with over $20 billion of capital under management. For over 20 years, the firm has provided credit to help medium-sized U.S. businesses grow. The firm’s award-winning middle market lending business helps provide financing for middle market companies and their private equity sponsors. Golub Capital’s credit expertise also forms the foundation of its Late State Lending and Broadly Syndicated Loan businesses.
Golub Capital has worked hard to build a reputation as a fast, reliable provider of compelling financing solutions, and we believe this has inspired repeat clients and investors. Today, the firm has over 300 employees with lending offices in Chicago, New York and San Francisco.Latest NewsRevenue in the U.S. Middle Market Grew by 8.94% in Q2 2017, According to the Golub Capital Middle Market ReportMiddle market private companies in the Golub Capital Altman Index experienced year-over-year revenue growth of 8.94% and earnings (defined as earnings before interest, taxes, depreciation and amortization, or "EBITDA") growth...Read moreGolub Capital BDC, Inc. Announces $241.9 Million In New Middle-Market Originations For Its Fiscal Year 2017 Third QuarterGolub Capital BDC, Inc. (NASDAQ: GBDC, www.golubcapitalbdc.com), a business development company, today announced that it originated $241.9 million in new middle-market investment commitments during the three months ended June 30,...Read moreThe Case for Middle Market Lending By: David GolubRead more
Golub Capital BDC INC.Golub Capital BDC, Inc. Schedules Release of Fiscal Year 2017 Third Quarter ResultsGolub Capital BDC, Inc., a business development company (NASDAQ: GBDC, www.golubcapitalbdc.com), announced today that it will report its financial results for the fiscal quarter ended June 30, 2017 on Monday,...Read moreGolub Capital BDC, Inc. Prices Public Offering Of 1,750,000 Shares Of Common StockGolub Capital BDC, Inc. (the "Company"), a business development company (NASDAQ: GBDC), announced that it has priced an underwritten, public offering of 1,750,000 shares of its common stock. UBS Investment...Read moreGolub Capital BDC, Inc. (NASDAQ: GBDC) is a business development company that makes debt and minority equity investments in middle-market companies that are, in most cases, sponsored by private equity investors.Read more



















BrightScope | Advisor Pages - Find a Financial Advisor or Advisory Firm 































































[[getSearchTypeDisplayName(searchType)]]


Advisor

Funds

Firms

401k Plans









































































General Search










Advisors
Advisory Firms
Financial Q&A
401k Plans
Funds


Search










Home  >  BrightScope Advisor Pages  >  Find a Financial Advisory Firm
    




Advisor Search
Firm Search
Advisors by City


    
        Find a Financial Advisory Firm
    





Search




Firm Name







Active firms only





City



State


Alabama
Alaska
American Samoa
Arizona
Arkansas
California
Colorado
Connecticut
Delaware
District Of Columbia
Florida
Georgia
Guam
Hawaii
Idaho
Illinois
Indiana
Iowa
Kansas
Kentucky
Louisiana
Maine
Maryland
Massachusetts
Michigan
Minnesota
Mississippi
Missouri
Montana
Nebraska
Nevada
New Hampshire
New Jersey
New Mexico
New York
North Carolina
North Dakota
Northern Marinara Islands
Ohio
Oklahoma
Oregon
Pennsylvania
Puerto Rico
Rhode Island
South Carolina
South Dakota
Tennessee
Texas
Utah
Vermont
Virgin Islands
Virginia
Washington
West Virginia
Wisconsin
Wyoming



Firm Service Areas



Financial Planning



Estate Planning



Comprehensive Financial Planning



Retirement Planning



College Planning



Charitable Planning



Other Financial Planning



Tax Planning





Insurance



Life Insurance



Health Insurance



Long-Term Care Insurance



Annuities



Property & Casualty Insurance



Business Insurance



Other Insurance





Pension Consulting



401k



403b



457



Defined Benefit



Other Pension Consulting





Portfolio Management



Individuals and/or Small Businesses



Investment Companies



Businesses or Institutional Clients



Other Portfolio Management





Accounting & Tax



Tax Advice



Other Tax





Legal



Legal Planning



Legal Advice



Other Legal





Other



Publication of Periodicals or Newsletters



Security Ratings or Pricing Services



Market Timing Services



Selection of Other Advisors



Educational seminars/workshops







See All Service Areas

	                Find
	            





Filters

/financial-planning/find/firm/



Compensation Arrangements



No Preference



Fixed Fees (14,450)



Hourly Charges (12,502)



Performance-Based Fees (6,657)



None (3,396)



Fee Only (75)






Assets Under Mgmt.



No Preference



0 - 100K (22,026)



1M - 10M (4,729)



10M - 100M (9,354)



100M - 500M (5,820)



1B - 10B (2,642)






Avg Account Balance



No Preference



0 - 100K (24,601)



100K - 500K (11,251)



500K - 1M (3,090)



1M - 10M (3,577)



10M - 100M (2,704)






Financial Advisory Firm Search Results


48,033 results










Merrill Lynch, Pierce, Fenner & Smith Incorporated
Ny, NY



34,605 Advisors
 | 
AUM : $639.6B











Wells Fargo Advisors, LLC
St. Louis, MO



26,648 Advisors
 | 
AUM : $409.7B











J.P. Morgan Securities LLC
Manhattan, NY



25,629 Advisors
 | 
AUM : $81.6B











Morgan Stanley Smith Barney LLC
Harrison, NY



24,260 Advisors
 | 
AUM : $598.5B











LPL Financial LLC
Boston, MA



18,591 Advisors
 | 
AUM : $117.2B











Edward D. Jones & Co., L.P.
Des Peres, MO



18,681 Advisors
 | 
AUM : $204.2B











Ameriprise Financial Services, Inc.
Minneapolis, MN



14,082 Advisors
 | 
AUM : $198.0B











UBS Financial Services Inc.
Weehawken, NJ



12,618 Advisors
 | 
AUM : $391.7B











Northwestern Mutual Investment Services,LLC
Milwaukee, WI



9,126 Advisors











Charles Schwab & Co., Inc.
South Beach, CA



7,895 Advisors











Mml Investors Services, LLC
Pine Point, MA



7,845 Advisors
 | 
AUM : $25.6B











Goldman, Sachs & Co.
Ny, NY



7,642 Advisors
 | 
AUM : $198.8B











Strategic Advisers, Inc.
Boston, MA



6,967 Advisors
 | 
AUM : $254.0B











Citigroup Global Markets Inc.
New York, NY



6,930 Advisors
 | 
AUM : $20.2B











Raymond James & Associates, Inc.
St. Petersburg, FL



6,389 Advisors
 | 
AUM : $125.0B









1
2
3
4
5



















Company Info
            About Us

Newsroom

Careers

Contact

Blog





Explore
            401K Plan Ratings

Advisor Pages

Fund Pages

Financial Insights

FAQ





For Advisors
            Advisor Pages

Spyglass





For Enterprise
            Beacon





Social
            Facebook

Twitter

LinkedIn





Legal
            Privacy Policy

Terms of Use






Copyright © 2008-2017, BrightScope Inc. All Rights Reserved. Your use of this service is subject to ourTerms of UseandPrivacy Policy





Information is provided 'as is' and solely for informational purposes, not for investment purposes or advice.BrightScope is not a fiduciary under ERISA. BrightScope is not endorsed by or affiliated with FINRA.
        










BrightScope /
CIO /
FWW /
Global Custodian /
Investor Economics /
LiquidMetrix /
Market Metrics /
Matrix Solutions /
PLANADVISER /
Plan For Life /
PLANSPONSOR /
Simfund /
Strategic Insight /
The Trade

©2016 Strategic Insight Inc. All Rights Reserved. No Reproduction without Prior Authorizations








































Summit Partners, L.P. - Financial Services Firm, Boston, Massachusetts - BrightScope Advisor Pages































[[getSearchTypeDisplayName(searchType)]]


Advisor

Funds

Firms

401k Plans










































































Back to top



Home>FirmPages>Summit Partners, L.P.





Summit Partners, L.P.



OverviewArticlesHoldingsAssetsServicesAdvisorsLeadershipFees









Share


Summit Partners, L.P.









OverviewArticlesHoldingsAssetsServicesAdvisorsLeadershipFees








Overview







Description
        
 Summit Partners, L.P. is a RIA based in Boston, MA with $13B in AUM.











Information


Type
RIA


HEAD QUARTERS
   Boston, MA 




# OF EMPLOYEES
149


Total Assets
$12,669,957,319



Website







Location
        



222 Berkeley St


Boston,
MA
02116


617-824-1000









Articles







Insights




There are no insights from this firm to display at this time.






Procter & Gamble Plans Competitive, But Exposure to Company Stock a Risk to Participants
BrightScope Editorial






Firm Links




There are no links for this firm to display at this time.









Holdings







ETF Holdings




There is no ETF holding data from this firm to display at this time.










Assets







Assets
Last updated on May 2, 2017





$12.7B
Total Assets Under Management


N/A
Total Assets Under Advisement






40

          
Accounts
          


$316.7M

          
Estimated Average Account Balance
          













Services







Firm Services
        




There is no Services data available to display at this time.








Firm Client types







Advisors









Current Advisors


# of advisors
0






There are no advisors from this firm to display at this time.





















Affiliated Investment Advisors and Broker Dealers



Name

Type

Total Assets





Summit Accelerator Partners, LLC
              
IAR
              
$67,781,256
              


Summit Investors Management, LLC
              
--
              
--
              


Summit Partners Credit Advisors, L.P.
              
IAR
              
$1,161,097,589
              


Summit Partners Ege Ii, S.A.R.L
              
--
              
--
              


Summit Partners Entrepreneur Advisors Gp Ii, LLC
              
--
              
--
              


Summit Partners Entrepreneur Advisors Gp, LLC
              
--
              
--
              


Summit Partners Europe, L.P.
              
IAR
              
$274,610,133
              


Summit Partners Ge Ix, L.P.
              
--
              
--
              


Summit Partners Ge VIII Aiv, L.P.
              
--
              
--
              


Summit Partners Ge Viii, L.P.
              
IAR
              
$0
              


Summit Partners LLP
              
--
              
--
              


Summit Partners Pe Vii, L.P.
              
IAR
              
$2,292,231,873
              


Summit Partners Public Asset Management, LLC
              
IAR
              
$540,245,829
              


Summit Partners Sd Iii, L.P.
              
IAR
              
$288,177,654
              


Summit Partners Sd Iv, L.P.
              
IAR
              
$121,486,019
              


Summit Partners V, L.P.
              
IAR
              
$21,845,180
              


Summit Partners Vc Ii, L.P.
              
IAR
              
$238,902,492
              


Summit Partners Vc Iii, L.P.
              
IAR
              
$0
              


Summit Partners Vc Iv, L.P.
              
--
              
--
              


Summit Partners VI (Gp), L.P.
              
IAR
              
$1,897,510,785
              


Summit Partners, LLC
              
IAR
              
$89,626,436
              



















Leadership







Ownership




There is no ownership data available to display at this time.






Executives and Control Persons




Name

Title

Tenure Date

% Ownership





Walter German Kortschak

Limited Partner
      
August, 1999
      
5% to 10%
      


Robert G. Bannish

Personal Representative Of The The Estate Of Joseph F. Trustey
      
August, 2015
      
5% to 10%
      


James Richard Westra

Personal Representative Of The The Estate Of Joseph F. Trustey
      
August, 2015
      
5% to 10%
      


Scott Charles Collins

Limited Partner
      
August, 1999
      
5% to 10%
      


Peter Y Chung

Limited Partner
      
August, 1999
      
5% to 10%
      


Bruce Roger Evans

Limited Partner
      
August, 1999
      
5% to 10%
      


Thomas Scott Roberts

Limited Partner
      
August, 1999
      
5% to 10%
      


Martin Joseph Mannion

Limited Partner
      
August, 1999
      
5% to 10%
      


Robin Winters Devereux

Chief Compliance Officer
      
April, 2005
      
less than 5%
      










Source: SEC








Fees






Types of Compensation Arrangements


Percentage Of Assets

Performance-Based Fees


















Company Info
            About Us

Newsroom

Careers

Contact

Blog





Explore
            401K Plan Ratings

Advisor Pages

Fund Pages

Financial Insights

FAQ





For Advisors
            Advisor Pages

Spyglass





For Enterprise
            Beacon





Social
            Facebook

Twitter

LinkedIn





Legal
            Privacy Policy

Terms of Use






Copyright © 2008-2017, BrightScope Inc. All Rights Reserved. Your use of this service is subject to ourTerms of UseandPrivacy Policy





Information is provided 'as is' and solely for informational purposes, not for investment purposes or advice.BrightScope is not a fiduciary under ERISA. BrightScope is not endorsed by or affiliated with FINRA.
        










BrightScope /
CIO /
FWW /
Global Custodian /
Investor Economics /
LiquidMetrix /
Market Metrics /
Matrix Solutions /
PLANADVISER /
Plan For Life /
PLANSPONSOR /
Simfund /
Strategic Insight /
The Trade

©2016 Strategic Insight Inc. All Rights Reserved. No Reproduction without Prior Authorizations


















































Summit Partners, L.P. - Financial Services Firm, Boston, Massachusetts - BrightScope Advisor Pages































[[getSearchTypeDisplayName(searchType)]]


Advisor

Funds

Firms

401k Plans










































































Back to top



Home>FirmPages>Summit Partners, L.P.





Summit Partners, L.P.



OverviewArticlesHoldingsAssetsServicesAdvisorsLeadershipFees









Share


Summit Partners, L.P.









OverviewArticlesHoldingsAssetsServicesAdvisorsLeadershipFees








Overview







Description
        
 Summit Partners, L.P. is a RIA based in Boston, MA with $13B in AUM.











Information


Type
RIA


HEAD QUARTERS
   Boston, MA 




# OF EMPLOYEES
149


Total Assets
$12,669,957,319



Website







Location
        



222 Berkeley St


Boston,
MA
02116


617-824-1000









Articles







Insights




There are no insights from this firm to display at this time.






Procter & Gamble Plans Competitive, But Exposure to Company Stock a Risk to Participants
BrightScope Editorial






Firm Links




There are no links for this firm to display at this time.









Holdings







ETF Holdings




There is no ETF holding data from this firm to display at this time.










Assets







Assets
Last updated on May 2, 2017





$12.7B
Total Assets Under Management


N/A
Total Assets Under Advisement






40

          
Accounts
          


$316.7M

          
Estimated Average Account Balance
          













Services







Firm Services
        




There is no Services data available to display at this time.








Firm Client types







Advisors









Current Advisors


# of advisors
0






There are no advisors from this firm to display at this time.





















Affiliated Investment Advisors and Broker Dealers



Name

Type

Total Assets





Summit Accelerator Partners, LLC
              
IAR
              
$67,781,256
              


Summit Investors Management, LLC
              
--
              
--
              


Summit Partners Credit Advisors, L.P.
              
IAR
              
$1,161,097,589
              


Summit Partners Ege Ii, S.A.R.L
              
--
              
--
              


Summit Partners Entrepreneur Advisors Gp Ii, LLC
              
--
              
--
              


Summit Partners Entrepreneur Advisors Gp, LLC
              
--
              
--
              


Summit Partners Europe, L.P.
              
IAR
              
$274,610,133
              


Summit Partners Ge Ix, L.P.
              
--
              
--
              


Summit Partners Ge VIII Aiv, L.P.
              
--
              
--
              


Summit Partners Ge Viii, L.P.
              
IAR
              
$0
              


Summit Partners LLP
              
--
              
--
              


Summit Partners Pe Vii, L.P.
              
IAR
              
$2,292,231,873
              


Summit Partners Public Asset Management, LLC
              
IAR
              
$540,245,829
              


Summit Partners Sd Iii, L.P.
              
IAR
              
$288,177,654
              


Summit Partners Sd Iv, L.P.
              
IAR
              
$121,486,019
              


Summit Partners V, L.P.
              
IAR
              
$21,845,180
              


Summit Partners Vc Ii, L.P.
              
IAR
              
$238,902,492
              


Summit Partners Vc Iii, L.P.
              
IAR
              
$0
              


Summit Partners Vc Iv, L.P.
              
--
              
--
              


Summit Partners VI (Gp), L.P.
              
IAR
              
$1,897,510,785
              


Summit Partners, LLC
              
IAR
              
$89,626,436
              



















Leadership







Ownership




There is no ownership data available to display at this time.






Executives and Control Persons




Name

Title

Tenure Date

% Ownership





Walter German Kortschak

Limited Partner
      
August, 1999
      
5% to 10%
      


Robert G. Bannish

Personal Representative Of The The Estate Of Joseph F. Trustey
      
August, 2015
      
5% to 10%
      


James Richard Westra

Personal Representative Of The The Estate Of Joseph F. Trustey
      
August, 2015
      
5% to 10%
      


Scott Charles Collins

Limited Partner
      
August, 1999
      
5% to 10%
      


Peter Y Chung

Limited Partner
      
August, 1999
      
5% to 10%
      


Bruce Roger Evans

Limited Partner
      
August, 1999
      
5% to 10%
      


Thomas Scott Roberts

Limited Partner
      
August, 1999
      
5% to 10%
      


Martin Joseph Mannion

Limited Partner
      
August, 1999
      
5% to 10%
      


Robin Winters Devereux

Chief Compliance Officer
      
April, 2005
      
less than 5%
      










Source: SEC








Fees






Types of Compensation Arrangements


Percentage Of Assets

Performance-Based Fees


















Company Info
            About Us

Newsroom

Careers

Contact

Blog





Explore
            401K Plan Ratings

Advisor Pages

Fund Pages

Financial Insights

FAQ





For Advisors
            Advisor Pages

Spyglass





For Enterprise
            Beacon





Social
            Facebook

Twitter

LinkedIn





Legal
            Privacy Policy

Terms of Use






Copyright © 2008-2017, BrightScope Inc. All Rights Reserved. Your use of this service is subject to ourTerms of UseandPrivacy Policy





Information is provided 'as is' and solely for informational purposes, not for investment purposes or advice.BrightScope is not a fiduciary under ERISA. BrightScope is not endorsed by or affiliated with FINRA.
        










BrightScope /
CIO /
FWW /
Global Custodian /
Investor Economics /
LiquidMetrix /
Market Metrics /
Matrix Solutions /
PLANADVISER /
Plan For Life /
PLANSPONSOR /
Simfund /
Strategic Insight /
The Trade

©2016 Strategic Insight Inc. All Rights Reserved. No Reproduction without Prior Authorizations

































 

Summit Investors Ge Ix/vc Iv Llc - Funding history, company info, news ...































Want to see more?Want to find out who got funded, and who’s funding the next big thing? in real time? all across the world? tailored to your specific areas of focus?100+ deals per dayGet access to the most exhaustive worldwide funding watch on the web!Comprehensive funding informationKnow about who invested in a company, which sites covered the event, the funding history, etc.Exclusive insightsView original analytics such as most dynamic industries, most active investors, and more!Stay aware!Get emailed when deals critical to your business happen. Filter by region, industry and topics of interest.As seen onHave a login?Sign inRegister now!It's free!Use your social accountOr fill in the quick form:Register nowpromise we won't spamSign invia your social account:via your existing WGF account:Remember meRegister, it's freeForgot your password?SIGN INForgot your password?Enter your e-mail and we will send you your new password.reset passwordThe world's largest funding base/companies/211846-summit-investors-ge-ixvc-iv-llcsection=companies&subsection=detail&id=211846  




			Search deals by company name, industry, location, investors...			
			




SEARCH


Summit Investors Ge Ix/vc Iv LlcCompany DetailsGet alertedif Summit Investors Ge Ix/vc Iv Llc gets funded!Summit Investors Ge Ix/vc Iv LlcFunding history Key peopleCountry:State:City:United StatesMassachusettsBostonIndustry:Finance Funding history DateDeal sizeInvestors September 28th, 2015Undisclosed-View DealCreate alertManage your alerts in accountWant to know when Summit Investors Ge Ix/vc Iv Llc gets funded?Key peopleRobin DevereuxExecutive OfficerBruce EvansExecutive OfficerLeonard FerringtonExecutive OfficerCharles FitzgeraldExecutive OfficerJames FreelandExecutive OfficerTodd HearleExecutive OfficerWalter KortschakExecutive OfficerMartin MannionExecutive OfficerPETER ROTTIERExecutive OfficerAlexander WhittemoreExecutive OfficerPlease note that all data is automatically extracted and errors can occur.The WhoGotFunded team has not necessarily reviewed the information in this page and has not determined if it is accurate and complete.Inaccurate Data? Help us improve WhoGotFunded: post a comment!





Investor's Business Daily | Stock News & Stock Market Analysis - IBD












































































Market Trend

Market Trend

The Big Picture
Stock Market Today
IBD's ETF Market Strategy
Psychological Market Indicators




Stock Lists

Stock Lists

My Stock Lists
IBD Big Cap 20
IPO Leaders
Stocks Near A Buy Zone
IBD 50
New Highs
Global Leaders
Your Weekly Review
Sector Leaders
Relative Strength at New High
Rising Profit Estimates
Tech Leaders
Stock Spotlight
CAN SLIM Select
Stocks that Funds are Buying
IBD Data Tables
Stocks On The Move




Research

Stock Research

IBD Stock Checkup
IBD Charts
ETFs & Funds
Investing Action Plan
The Income Investor
ETF Center
Earnings Preview
Industry Snapshot
IBD Industry Themes
Earnings Calendar
Short Selling
Futures & Options
IBD Stock Analysis
Swing Trading
Bonds
The New America
IBD Data Stories


Premium Investing Tools

Leaderboard
Swing Trader
eTables
Top Rated Stocks Under $10
MarketSmith




News

NEWS

eIBD
Best ETFs
Technology
ETF Leaders
Click Tech Blog
Best Mutual Funds
FANG Stocks News
Economy
Retirement
Economic Calendar
Personal Finance
Real Estate
Financial Advisor Briefing
Special Reports
Management
Industry News Pages


Politics

Politics
Editorials
Trump News & Tweets
Commentary
The Trump Economy
Columnists
Economic Optimism Index
Policy & Analysis
IBD/TIPP Poll




IBD Videos

IBD Videos

Investing Videos
Home Study Programs




How to Invest

Lesson Topics

Getting Started with IBD
The CAN SLIM Investing System
How to Time the Stock Market
How to Find and Evaluate Stocks
How to Read Stock Charts
How to Buy Stocks
How to Sell Stocks
Swing Trading


Educational Resources

New to IBD
IBD Meetups
Ask IBD
Investor's Corner
IBD Key Terms
IBD Live Workshops
IBD Home Study Courses
Webinars




Leaderboard
Swing Trader
MarketSmith
Store





BREAKING: Techs Lead Stocks Modestly Lower  | Tobacco Stocks Dive As FDA To Lower Nicotine Levels
 








































Shopping Cart

Your cart is currently empty. Visit the IBD Store to get
started.













Market Trend

Market Trend

The Big Picture
Stock Market Today
IBD's ETF Market Strategy
Psychological Market Indicators




Stock Lists

Stock Lists

My Stock Lists
IBD Big Cap 20
IPO Leaders
Stocks Near A Buy Zone
IBD 50
New Highs
Global Leaders
Your Weekly Review
Sector Leaders
Relative Strength at New High
Rising Profit Estimates
Tech Leaders
Stock Spotlight
CAN SLIM Select
Stocks that Funds are Buying
IBD Data Tables
Stocks On The Move




Research

Stock Research

IBD Stock Checkup
IBD Charts
ETFs & Funds
Investing Action Plan
The Income Investor
ETF Center
Earnings Preview
Industry Snapshot
IBD Industry Themes
Earnings Calendar
Short Selling
Futures & Options
IBD Stock Analysis
Swing Trading
Bonds
The New America
IBD Data Stories


Premium Investing Tools

Leaderboard
Swing Trader
eTables
Top Rated Stocks Under $10
MarketSmith




News

NEWS

eIBD
Best ETFs
Technology
ETF Leaders
Click Tech Blog
Best Mutual Funds
FANG Stocks News
Economy
Retirement
Economic Calendar
Personal Finance
Real Estate
Financial Advisor Briefing
Special Reports
Management
Industry News Pages


Politics

Politics
Editorials
Trump News & Tweets
Commentary
The Trump Economy
Columnists
Economic Optimism Index
Policy & Analysis
IBD/TIPP Poll




IBD Videos

IBD Videos

Investing Videos
Home Study Programs




How to Invest

Lesson Topics

Getting Started with IBD
The CAN SLIM Investing System
How to Time the Stock Market
How to Find and Evaluate Stocks
How to Read Stock Charts
How to Buy Stocks
How to Sell Stocks
Swing Trading


Educational Resources

New to IBD
IBD Meetups
Ask IBD
Investor's Corner
IBD Key Terms
IBD Live Workshops
IBD Home Study Courses
Webinars




Leaderboard
Swing Trader
MarketSmith
Store



Hi 

MY IBD
SIGN OUT


My Products
My Favorites
My Stock Lists







Edit








Sign In


Shopping Cart














Hi 

SIGN OUT


My Products






My Favorites
Edit





My Stock Lists

























Indexes Mostly Down; GOP Health Failure Hurts This Stock







As Alibaba Bounces Back, This Chinese Stock May Soon Break Out 



Is The Holy Grail Of Digital Payments One Click Away? 



Apple Headlines Busy Week Of Earnings And Potential Option Trades 



As PayPal, Square Rise, This Prepaid Card Stock May Cash In 



FDA Acts Vs. Cigarettes, But One Tobacco Giant Is Holding Up 










Mastercard, Visa Make Big Cap 20; Both Still Early Stage 










Chevron, Exxon Stay Aggressive In Permian; 'Not Holding Back' 










Amazon Miss Sparks Debate: Will Video Pay Off Like Cloud Computing? 









Get IBD's Newsletters delivered to your inbox daily.

Thanks! You'll start receiving the best of IBD in your Inbox.






Please select a newsletter to subscribe to




 Market Prep





 Tech Report









Sign Up 



Please enter a valid email address

Get these newsletters delivered to your inbox and more info about our products and services. Privacy Policy






















TODAY'S SPOTLIGHT





Best Online Broker Survey
IBD wants to know how satisfied you are with your online broker. Begin Survey!







 Get MarketSmith Premium
Sink your teeth into profits when you catch the next big stock winner. Take a 4-week trial for just $29.95. Try MarketSmith today!







Signs Your Stock May Be Topping
In this free webinar, we cover three signs of weakness: Reversal Days, Stalling and Churning. Watch archive.















MARKET TREND




 

STOCK MARKET TODAY
Indexes Mostly Down; GOP Health Failure Hurts This Stock 12:11 PM ETEdwards Lifesciences may have been hurt because of the defeat of the Republican "skinny" repeal...                    
                






STOCK LISTS
Best Stocks To Buy And Watch                    
9:03 AM ET Build and maintain your watch list with the latest news and analysis of the market's...
                    







RESEARCH
Earnings Calendar, Analyst Estimates And Stocks To Watch                    
8:36 AM ET Build your watch list and action plan with a look at stocks set to report.
                    








See what adding futures can do for your trading strategy.
Understand the markets. Try our practice simulator. Then start trading. 
Everything you need to add futures and capitalize on new opportunities 
is right here.
Promoted Content By 
CME Group















IBD STOCK LISTS







Sector Leaders
IBD’s most stringent and powerful screen, Sector Leaders highlight the best stocks in IBD’s 33 sectors. All Sector Leaders show outstanding earnings and sales growth in recent quarters and are strong across many other fundamental and price-performance metrics.





 AbbVie's Humira Hit The Brake In Q2; Stock Dives
AbbVie topped second-quarter sales and adjusted profits expectations early Friday. 
AbbVie topped second-quarter sales and adjusted profits expectations early Friday. 






These 3 Europe-Tracking ETFs Climb Near Buy Points                    
The major European stock indexes have been trending lower for weeks or months, but three ETFs that track the continent... 
The major European stock indexes have been trending lower for... 




Selling Leaves These 5 Spotlight Stocks Back Near Buy Points                    
A turnabout day on the market left IBD’s Stock Spotlight list showing some resilience and some stocks back near or... 
A turnabout day on the market left IBD’s Stock Spotlight... 


 
AstraZeneca Beats, But Stock Dives On Drug Failure; 4 More Report                    
AstraZeneca topped profit views, but shares crashed on an immuno-oncology setback. Roche also beat. 
AstraZeneca topped profit views, but shares crashed on an immuno-oncology... 





































INVESTING RESOURCES







SUBSCRIBE TO THEIBD DIGITAL EDITION
Get 4 free weeks of the IBD Digital edition plus access to IBD's exclusive market analysis, proprietary stock ratings and interactive tools.








 WATCH, LEARN AND LISTEN WITH IBD VIDEOS
Stay on top of the market with IBD's exclusive videos. You will find the latest news, market analysis, and education to help you become a more successful investor.








GETTING STARTED WITH IBD
Get the most out of  IBD's products and features by learning the CAN SLIM Investing System and staying in sync with the market trend.









